228 related articles for article (PubMed ID: 29663354)
1. The management of livedoid vasculopathy focused on direct oral anticoagulants (DOACs): four case reports successfully treated with rivaroxaban.
Franco Marques G; Criado PR; Alves Batista Morita TC; Cajas García MS
Int J Dermatol; 2018 Jun; 57(6):732-741. PubMed ID: 29663354
[TBL] [Abstract][Full Text] [Related]
2. Livedoid vasculopathy - current aspects of diagnosis and treatment of cutaneous infarction.
Kerk N; Goerge T
J Dtsch Dermatol Ges; 2013 May; 11(5):407-10. PubMed ID: 23437985
[TBL] [Abstract][Full Text] [Related]
3. [Livedoid vasculopathy. Pathogenesis, diagnosis and treatment of cutaneous infarction].
Goerge T
Hautarzt; 2011 Aug; 62(8):627-34; quiz 635. PubMed ID: 21786003
[TBL] [Abstract][Full Text] [Related]
4. Livedoid vasculopathy - a thrombotic disease.
Kerk N; Goerge T
Vasa; 2013 Sep; 42(5):317-22. PubMed ID: 23989066
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Livedoid Vasculopathy With Rivaroxaban: A Potential Use of New Oral Anticoagulants for Dermatologists.
Jiménez-Gallo D; Villegas-Romero I; Rodríguez-Mateos ME; Linares-Barrios M
Actas Dermosifiliogr (Engl Ed); 2018 Apr; 109(3):278-281. PubMed ID: 29074145
[No Abstract] [Full Text] [Related]
6. Anticoagulation with rivaroxaban for livedoid vasculopathy (RILIVA): a multicentre, single-arm, open-label, phase 2a, proof-of-concept trial.
Weishaupt C; Strölin A; Kahle B; Kreuter A; Schneider SW; Gerss J; Eveslage M; Drabik A; Goerge T
Lancet Haematol; 2016 Feb; 3(2):e72-9. PubMed ID: 26853646
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of intravenous immunoglobulins in livedoid vasculopathy: long-term follow-up of 11 patients.
Monshi B; Posch C; Vujic I; Sesti A; Sobotka S; Rappersberger K
J Am Acad Dermatol; 2014 Oct; 71(4):738-44. PubMed ID: 25022849
[TBL] [Abstract][Full Text] [Related]
8. Livedoid vasculopathy: an in-depth analysis using a modified Delphi approach.
Alavi A; Hafner J; Dutz JP; Mayer D; Sibbald RG; Criado PR; Senet P; Callen JP; Phillips TJ; Romanelli M; Kirsner RS
J Am Acad Dermatol; 2013 Dec; 69(6):1033-1042.e1. PubMed ID: 24028907
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of new low-dose oral anticoagulants in recalcitrant livedoid vasculopathy.
Furukawa F; Mizawa M; Makino T; Shimizu T
BMJ Case Rep; 2017 Jul; 2017():. PubMed ID: 28739563
[TBL] [Abstract][Full Text] [Related]
10. Livedoid vasculopathy as a coagulation disorder.
Criado PR; Rivitti EA; Sotto MN; de Carvalho JF
Autoimmun Rev; 2011 Apr; 10(6):353-60. PubMed ID: 21184847
[TBL] [Abstract][Full Text] [Related]
11. Livedoid vasculopathy: an intringuing cutaneous disease.
Criado PR; Rivitti EA; Sotto MN; Valente NY; Aoki V; Carvalho JF; Vasconcellos C
An Bras Dermatol; 2011; 86(5):961-77. PubMed ID: 22147037
[TBL] [Abstract][Full Text] [Related]
12. Case of livedoid vasculopathy with peripheral neuropathy successfully treated with low-dose warfarin.
Osada S; Kimura Y; Kawana S
J Dermatol; 2010 Jan; 37(1):98-101. PubMed ID: 20175830
[TBL] [Abstract][Full Text] [Related]
13. Characteristics, risk factors and treatment reality in livedoid vasculopathy - a multicentre analysis.
Weishaupt C; Strölin A; Kahle B; Kreuter A; Schneider SW; Gerss J; Eveslage M; Drabik A; Goerge T
J Eur Acad Dermatol Venereol; 2019 Sep; 33(9):1784-1791. PubMed ID: 31009111
[TBL] [Abstract][Full Text] [Related]
14. Prevention of livedoid vasculopathy recurrence by prolonged administration of rivaroxaban.
Drerup C; Goerge T
J Eur Acad Dermatol Venereol; 2017 Dec; 31(12):e532. PubMed ID: 28609556
[No Abstract] [Full Text] [Related]
15. Rivaroxaban prevents painful cutaneous infarctions in livedoid vasculopathy.
Kerk N; Drabik A; Luger TA; Schneider SW; Goerge T
Br J Dermatol; 2013 Apr; 168(4):898-9. PubMed ID: 23106384
[No Abstract] [Full Text] [Related]
16. Unilateral livedoid vasculopathy associated with involutional phase of cutaneous infantile hemangioma: the connection to coagulation disorders.
Criado PR; Alavi A; Halpern I; Sotto MN; Kirsner RS
Int J Low Extrem Wounds; 2013 Dec; 12(4):306-9. PubMed ID: 24043683
[TBL] [Abstract][Full Text] [Related]
17. Treatment application of rivaroxaban in Chinese patients with livedoid vasculopathy.
Chen W; Fan L; Wang Y; Deng X
J Pain Res; 2017; 10():621-624. PubMed ID: 28360530
[TBL] [Abstract][Full Text] [Related]
18. Successful Treatment of Painful Cutaneous Vasculopathy With Rivaroxaban in a Patient With Systemic Lupus Erythematosus.
Leisenring NH; Rogers JL; Telloni S; Mansoori P; Al-Rohil RN; Marano AL
J Drugs Dermatol; 2020 May; 19(5):544-546. PubMed ID: 32484618
[TBL] [Abstract][Full Text] [Related]
19. Homeopathic treatment in resistant livedoid vasculopathy: case report.
Waisse-Priven S; Jurj G; Lima Thomaz LC; Tierno SA; Filho WL; Sos AB
Homeopathy; 2009 Jul; 98(3):165-8. PubMed ID: 19647211
[TBL] [Abstract][Full Text] [Related]
20. Prevention of recurrent ulceration of livedoid vasculopathy with long-term apixaban monotherapy.
Osada SI; Ishikawa N; Hasunuma N; Manabe M
J Dermatol; 2019 Apr; 46(4):e142-e143. PubMed ID: 30156315
[No Abstract] [Full Text] [Related]
[Next] [New Search]
